Diaceutics PLC (LON:DXRX) Insider Buys £149.76 in Stock

Diaceutics PLC (LON:DXRX) insider Jordan Clark bought 104 shares of the business’s stock in a transaction on Tuesday, January 28th. The stock was bought at an average price of GBX 144 ($1.79) per share, with a total value of £149.76 ($185.99).

Diaceutics Price Performance

LON DXRX opened at GBX 135.50 ($1.68) on Friday. The company has a quick ratio of 9.92, a current ratio of 4.85 and a debt-to-equity ratio of 2.93. The stock has a market capitalization of £114.46 million, a PE ratio of -4,516.67 and a beta of 0.58. Diaceutics PLC has a 12-month low of GBX 92.24 ($1.15) and a 12-month high of GBX 151 ($1.88). The company has a 50 day moving average price of GBX 129.50 and a two-hundred day moving average price of GBX 128.53.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Canaccord Genuity Group reiterated a “buy” rating and set a GBX 160 ($1.99) price objective on shares of Diaceutics in a report on Tuesday, December 17th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a GBX 160 ($1.99) target price on shares of Diaceutics in a research report on Tuesday, December 17th.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.